Full Text View
Tabular View
No Study Results Posted
Related Studies
Safety and Tolerability of MS-R001 in Patients With Diabetic Macular Edema Secondary to Diabetic Retinopathy
This study has been completed.
Study NCT00401115   Information provided by Santen Inc.

First Received on November 15, 2006.   Last Updated on July 22, 2010   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Diabetic Macular Edema
Diabetic Retinopathy
Additional conditions recognized in this trial
Edema
Macular Edema
Retinal Diseases
More general conditions related to this trial
Cardiovascular Diseases
Diabetes Complications
Diabetes Mellitus
Diabetic Angiopathies
Endocrine System Diseases
Eye Diseases
Macular Degeneration
Retinal Degeneration
Signs and Symptoms
Vascular Diseases
Interventions listed in this trial
MS-R001 (rapamycin)
Additional drug interventions recognized in this trial
Everolimus
Sirolimus
More general drug interventions related to this trial
Anti-Bacterial Agents
Anti-Infective Agents
Antibiotics, Antineoplastic
Antifungal Agents
Antineoplastic Agents
Immunologic Factors
Immunosuppressive Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Santen Inc.
MacuSight, Inc.


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services